Calidi Biotherapeutics shares are trading lower after the company announced the pricing of a $6.1 million public offering.
Portfolio Pulse from Benzinga Newsdesk
Calidi Biotherapeutics shares are trading lower following the announcement of a $6.1 million public offering.
April 16, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Calidi Biotherapeutics' stock price is expected to face downward pressure in the short term due to the announcement of a $6.1 million public offering.
Public offerings often lead to short-term stock price declines due to the dilution of existing shares and the perception of financial need by the company. Given the direct impact of this news on Calidi Biotherapeutics, a negative short-term price movement is likely.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100